Staff Reports
For years, Americans joked about being the land of plenty — and the land of expanding waistlines. Now a new set of numbers suggests that a drug revolution may be nudging those waistlines in the other direction. The headline: GLP-1 medicines like Ozempic and Wegovy are being prescribed a lot more, and some datasets show obesity rates easing down a bit. That is big news, and it deserves a clear-eyed take.
New data: GLP-1 prescriptions are surging
EPIC Research dug into electronic health records and found prescriptions for GLP-1 drugs jumped from about 1,884 to roughly 8,819 per 100,000 adult patients between mid-2021 and early 2026. At the same time, EPIC’s sample shows the share of adults labeled obese slipping modestly. Gallup’s survey data backs a similar sign of change, with their national estimate of adult obesity falling from nearly 40% to about 37%. And a KFF poll says roughly 12% of adults now report taking a GLP-1 drug. Those are the facts on the table: more semaglutide, tirzepatide and related prescriptions, and some measurable shifts in obesity rates.
What’s really driving the numbers
Make no mistake: the arrival of oral GLP-1 pills has changed the game. New oral formulations — the first of their kind for weight loss — and growing competition have made it easier for doctors to prescribe and patients to try these medicines. That explains part of the big spike in prescriptions. But bigger prescription counts don’t automatically mean a permanent cure for America’s obesity problem. Clinical trials show clear weight loss while patients take the drugs, and also show substantial weight regain for many people who stop. Correlation is real, causation is still a careful argument, and long-term results will matter far more than a few good quarters.
Access, cost, and the policy question
Here is where the politics and the policy collide. KFF finds half of people say GLP-1s are hard to afford. Insurance coverage is uneven. That means the benefit of these drugs can flow to those with means or better plans, not necessarily to those who need help most. Conservatives should like competition and market solutions, and competition is coming, but market alone won’t fix sticker shock overnight. If we want sustained, fair improvements in obesity rates, we need cheaper drugs, smarter coverage rules, and more focus on prevention — not just handing out weekly shots to whoever can pay.
So, yes: the early signs are promising. The rise in GLP-1 prescribing and a modest fall in obesity rates deserve cautious applause. But don’t break out the victory banners yet. These medicines help a lot while patients stay on them, and they expose a deeper problem — America’s health system still struggles with cost, coverage, and long-term care. The new drugs are a tool, not a tidy finish to a long fight. We should welcome progress. We should also demand policies that make progress real, permanent, and available to everyone, not just the folks who can afford the newest pill or shot.
